Helsinn, the Braglia fam­i­ly phar­ma, sees some big changes in lead­er­ship as it un­veils a new R&D strat­e­gy

For any­one who’s been pay­ing close at­ten­tion, Helsinn’s shift to tar­get­ed can­cer ther­a­pies has been a long time com­ing. But on Thurs­day, the com­pa­ny of­fi­cial­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER